The Tox Lab

The Tox Lab

The Tox Lab is a podcast dedicated to exploring the science of toxicology and its real-world implications. Each week we aim to break down complex research, investigate real-life cases, and discuss emerging trends in toxicology. Disclaimer: All opinions are our own. Find us on instagram: @the_tox_lab Email us here: thetoxlab@gmail.com

  1. 3d ago

    Episode 85: Benzodiazepines and Alcohol: Does Cross-Tolerance Work Both Ways?

    This week on The Tox Lab, we're discussing cross-tolerance, focusing on the relationship between benzodiazepines and alcohol. We begin by exploring how alcohol acts at the GABA-A receptor, the neuroadaptations that occur with chronic alcohol use, and why the sudden cessation of alcohol can lead to withdrawal. We then discuss why benzodiazepines are the mainstay of treatment for alcohol withdrawal and the pharmacological basis for their effectiveness. We then turn to the concept of cross-tolerance, examining how long-term alcohol use can influence the response to benzodiazepines, and whether chronic benzodiazepine use provides similar cross-tolerance to the effects of alcohol. We discuss the pharmacological mechanisms underlying these interactions, the similarities and important differences between the two drugs, and why cross-tolerance is only partial. Finally, we consider the clinical implications of these findings, including why combining alcohol and benzodiazepines remains particularly dangerous despite any degree of tolerance. Join us as we examine the pharmacology, clinical toxicology, and misconceptions surrounding benzodiazepine and alcohol cross-tolerance, and consider what these interactions mean for patient care and overdose risk. Hope you enjoy! Link to papers we discussed: https://pmc.ncbi.nlm.nih.gov/articles/PMC3321276/  https://journals.healio.com/doi/10.3928/00485713-20251202-02?__cf_chl_f_tk=QOyw_fXXLTUEXO4ZHEuX5s6eAN_jQeaCPemdwZ_Ygdc-1783254633-1.0.1.1-n9t5ECBcZIAn9EM4ia88JllcRLiCinRKSrG5LRy3D94 Disclaimer: All opinions are our own. Find us on instagram: @the_tox_lab Email us here: thetoxlab@gmail.com Check out our new website: https://thetoxlab.co.uk/  Support us here: https://buymeacoffee.com/thetoxlab

  2. Jul 6

    Episode 84: MDMA: Why Does Toxicity Differ Between People?

    This week on The Tox Lab, we’re discussing MDMA, examining its pharmacology, toxicity, and the factors that influence individual susceptibility to harm. We begin by exploring how MDMA works, focusing on its effects on serotonin release, reuptake, and signalling, and the pharmacological mechanisms responsible for its desired effects and adverse reactions. We then examine a case of severe MDMA toxicity resulting in hyperthermia and multi-organ failure, discussing the clinical features, management, and the toxicological mechanisms underlying these life-threatening complications. Finally, we turn to the role of the polymorphic enzyme CYP2D6 in MDMA metabolism, examining how genetic variation and MDMA-induced inhibition of CYP2D6 can influence drug concentrations, toxicity, and the risks associated with repeat dosing and drug interactions. Join us as we examine the pharmacology, clinical toxicology, and pharmacogenetics of MDMA, and consider what these findings mean for understanding both its desired effects and its potential harms. Hope you enjoy! Links to the papers we discussed: https://pmc.ncbi.nlm.nih.gov/articles/PMC11470468/pdf/main.pdf https://pmc.ncbi.nlm.nih.gov/articles/PMC3495276/pdf/fgene-03-00235.pdf https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.2605  Disclaimer: All opinions are our own. Find us on instagram: @the_tox_lab Email us here: thetoxlab@gmail.com Check out our new website: https://thetoxlab.co.uk/  Support us here: https://buymeacoffee.com/thetoxlab

  3. Jun 29

    Episode 83: Grey Market Peptides – BPC-157, Melanotan II and Toxicity

    This week on The Tox Lab, we’re discussing grey market peptides and examining the growing interest in these compounds for performance enhancement, recovery, and cosmetic purposes. We begin by exploring peptides linked to musculoskeletal healing, focusing on BPC-157 and the evidence surrounding its proposed effects. We discuss the claims made about these compounds, the current state of the research, and the challenges of separating marketing from scientific evidence. We then turn to melanotan II, examining its pharmacology, patterns of use, and a rare case of priapism associated with its administration. Finally, we discuss the broader risks associated with grey market peptides, including product quality, dosing uncertainty, adverse effects, and the challenges posed by purchasing compounds from unregulated online sources. Join us as we examine the evidence, harms, and controversies surrounding grey market peptides, and consider what their increasing popularity means for toxicology, public health, and consumer safety. Hope you enjoy! Links to the papers we discussed: https://link.springer.com/article/10.1007/s12178-025-09990-7  https://academic.oup.com/smoa/article/9/1/100298/6956707   https://www.health.vic.gov.au/health-alerts/toxicity-linked-to-unapproved-peptide-retatrutide   Disclaimer: All opinions are our own. Find us on instagram: @the_tox_lab Email us here: thetoxlab@gmail.com Check out our new website: https://thetoxlab.co.uk/  Support us here: https://buymeacoffee.com/thetoxlab

  4. Jun 22

    Episode 82: Gabapentin and Pregabalin – Effectiveness, Trends and Toxicity

    This week on The Tox Lab, we’re discussing gabapentinoids and examining the use, effectiveness, and toxicological considerations surrounding gabapentin and pregabalin. Originally developed as anti-epileptic medications, gabapentinoids have become widely used for the treatment of neuropathic pain and a range of other conditions. We begin by examining prescribing trends and discussing the evidence surrounding their effectiveness, including whether these drugs are as beneficial as once thought in all patient groups. We then explore some of the adverse effects associated with gabapentinoids and discuss the risks associated with their use alongside other central nervous system depressants, including opioids and benzodiazepines. Finally, we turn to the forensic and toxicological aspects of gabapentinoid use, examining their involvement in driving under the influence of drugs cases and post-mortem investigations. We discuss what these findings tell us about the increasing prevalence of gabapentinoids and their role in drug-related deaths. Join us as we examine the benefits, limitations, and toxicological considerations surrounding gabapentin and pregabalin, and consider what their growing use means for patients and healthcare systems. Hope you enjoy! Links to the papers we discussed: https://pmc.ncbi.nlm.nih.gov/articles/PMC11626918/ https://shmpublications.onlinelibrary.wiley.com/doi/full/10.1002/jhm.70286 https://academic.oup.com/jat/advance-article-abstract/doi/10.1093/jat/bkag040/8703238?redirectedFrom=fulltext https://www.sciencedirect.com/science/article/pii/S037907382100150X?via%3Dihub Disclaimer: All opinions are our own. Find us on instagram: @the_tox_lab Email us here: thetoxlab@gmail.com Check out our new website: https://thetoxlab.co.uk/ Support us here: https://buymeacoffee.com/thetoxlab

  5. Jun 1

    Episode 80: Novel Benzodiazepines – Emerging Trends and Analytical Challenges

    This week on The Tox Lab, we’re discussing novel benzodiazepines and examining recent trends in their emergence and detection. We begin by exploring the origins of novel benzodiazepines, including how these compounds have entered the drug market and the factors contributing to their continued appearance. We then turn to a paper from the Society of Forensic Toxicologists (SOFT) Novel Psychoactive Substances Committee, examining trends in novel benzodiazepine detections between 2021 and 2025. We discuss findings from post-mortem investigations, clinical presentations, driving under the influence of drugs cases, and drug-facilitated crime, highlighting the compounds most commonly encountered, including bromazolam, etizolam, and desalkylgidazepam, and how patterns have changed over time. We also explore the analytical challenges associated with novel benzodiazepines, including their detection and identification in toxicology laboratories, the limitations of routine testing, and the difficulties associated with interpreting toxicological findings when limited pharmacological, toxicological, and concentration data are available. Join us as we examine the evolving landscape of novel benzodiazepines, consider the challenges they present for forensic and clinical toxicology, and discuss what these trends may tell us about the future of the drug market. Hope you enjoy! Links to the paper we discussed: https://academic.oup.com/jat/advance-article/doi/10.1093/jat/bkag026/8662327?searchresult=1 https://academic.oup.com/jat/advance-article-abstract/doi/10.1093/jat/bkag027/8663758?redirectedFrom=fulltext Disclaimer: All opinions are our own. Find us on instagram: @the_tox_lab Email us here: thetoxlab@gmail.com Check out our new website: https://thetoxlab.co.uk/ Support us here: https://buymeacoffee.com/thetoxlab

Ratings & Reviews

5
out of 5
2 Ratings

About

The Tox Lab is a podcast dedicated to exploring the science of toxicology and its real-world implications. Each week we aim to break down complex research, investigate real-life cases, and discuss emerging trends in toxicology. Disclaimer: All opinions are our own. Find us on instagram: @the_tox_lab Email us here: thetoxlab@gmail.com

You Might Also Like